If we are getting a partner of some sort, they would be not only investing in the drug, but also the team to continue development. If they are buying Cytodyn, they don’t really care about the team, they are getting the drug only and their team continues development. Given that the board has open slots, there is no real CEO, I would think a buyout is in our future. However, their are a few team members that are crucial to future development. Firing Nader and moving Kelly from chair, would sound like partnership.

Either way, if it is a buyout, no matter the price we can invest what ever we get in the buyer and contiune the leronlimab support. Unless it is some VC firm, then who knows.

I would also think that if it is a buyout, who it is matters. if it is a BP with a lot of pipeline overlap with leronlimab, they may just put it on a shelf. If it is a BP that wants to take market share from other BP, we might see leronlimab in the pharmacy quickly.